Test Overview
Test Methodology

Automated platelet induced aggregation.

Test Usage

To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.

Reference Range *

180 - 376 PRU. Values less than 180 PRU may be evidence of a P2Y12 inhibitor effect.

* Reference ranges may change over time. Please refer to the original patient report when evaluating results.

Test Limitations
  • Platelet counts less than 119K or more than 502K, and Hematocrit values less than 33% or greater than 52% can interfere with testing and valid results may not be obtained.
    The P2Y12 Platelet Function assay is not intended for use with inherited platelet disorders such as von Willebrand Factor Deficiency, Glanzmann Thrombasthenia and Bernard-Soulier Syndrome.
Test Details
Days Set Up
Daily, 24 hours
Analytic Time

1 hour

Soft Order Code
MiChart Code
Plavix Platelet Function Test
  • Ticagrelor Platelet Function Test
  • Ticlopidine (Ticlid) Platelet Function Test
  • Plavix Platelet Function Test
  • Verify Now P2Y12
  • P2Y12 Platelet Function Test
  • Clopidogrel (Plavix) Platelet Function Test
  • Thienopyridine Platelet Function Test
  • Prasurgrel Platelet Function Test
  • Brilinta (Ticagrelor)
Specimen Requirements
Collection Instructions

Collect specimen in a 2.7 mL blue top (citrate 3.2%) tube using a 21 gauge or larger needle. Mix by inversion. Do not centrifuge. Whole blood specimen should arrive at lab within 3 hours of collection; transport at room temperature. Collection of the blood through lines that have been previously flushed with heparin should be avoided. If the blood must be drawn through a VAD (vascular access device), the line should be flushed with 5 mL of saline and the first 5 mL of blood or six dead space volumes of the VAD discarded.

Special Handling


Patients who have been administered glycoprotein IIb/IIIa inhibitors tirofiban (Aggrastat) or eptifibatide (Integrilin) within the last 2 days or abciximab (ReoPro) within the last 2 weeks should not be tested.
Normal Volume
Full 2.7mL tube preferred, full 1.8mL tube is acceptable
Minimum Volume
Full 2.7mL tube preferred, full 1.8mL tube is acceptable
Rejection Criteria
Specimens will be rejected if not properly filled, clotted, grossly hemolyzed, or contaminated with heparin, or sent through the pneumatic tube system.
Additional Information

Surgical Screen: Patients administered anti-platelet therapies are at risk of increased bleeding during operations. It is recommended that patients on P2Y12 inhibitors undergoing surgery or invasive procedures be tested preoperatively. Test results may aid in decisions to initiate or delay surgery, and to make preparations for additional blood product use if surgery cannot be postponed. Therapeutic Response: Variability in patient response to anti-platelet drugs is common. It is recommended that patients on P2Y12 inhibitors be tested to determine if the drug has produced the expected antiplatelet effect.

CPT Code
Fee Code